Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

S. A. Watson; T. M. Morris; S. L. Parsons; R. J. Steele; P. D. Brown

doi:10.1038/bjc.1996.549

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

S. A. Watson, T. M. Morris, S. L. Parsons, R. J. Steele, P. D. Brown

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Abstract

The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P

Original language	English
Pages (from-to)	1354-1358
Number of pages	5
Journal	British Journal of Cancer
Volume	74
Issue number	9
DOIs	https://doi.org/10.1038/bjc.1996.549
Publication status	Published - 1996

Keywords

Animals
Antineoplastic Agents
Ascitic Fluid
Colorectal Neoplasms
Drug Screening Assays, Antitumor
Female
Humans
Metalloendopeptidases
Mice
Mice, SCID
Phenylalanine
Thiophenes
Tumor Cells, Cultured

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.1996.549

Cite this

@article{54aac97642be42e8b98b80a758ebe00b,

title = "Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model",

abstract = "The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P ",

keywords = "Animals, Antineoplastic Agents, Ascitic Fluid, Colorectal Neoplasms, Drug Screening Assays, Antitumor, Female, Humans, Metalloendopeptidases, Mice, Mice, SCID, Phenylalanine, Thiophenes, Tumor Cells, Cultured",

author = "Watson, {S. A.} and Morris, {T. M.} and Parsons, {S. L.} and Steele, {R. J.} and Brown, {P. D.}",

year = "1996",

doi = "10.1038/bjc.1996.549",

language = "English",

volume = "74",

pages = "1354--1358",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "9",

}

TY - JOUR

T1 - Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

AU - Watson, S. A.

AU - Morris, T. M.

AU - Parsons, S. L.

AU - Steele, R. J.

AU - Brown, P. D.

PY - 1996

Y1 - 1996

N2 - The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P

AB - The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 and 92 kDa forms of gelatinase by zymography. Batimastat administered from day 0 (40 mg kg-1) reduced the volume of ascites to 21% of control in mice treated from day 0 (P

KW - Animals

KW - Antineoplastic Agents

KW - Ascitic Fluid

KW - Colorectal Neoplasms

KW - Drug Screening Assays, Antitumor

KW - Female

KW - Humans

KW - Metalloendopeptidases

KW - Mice

KW - Mice, SCID

KW - Phenylalanine

KW - Thiophenes

KW - Tumor Cells, Cultured

U2 - 10.1038/bjc.1996.549

DO - 10.1038/bjc.1996.549

M3 - Article

C2 - 8912529

SN - 0007-0920

VL - 74

SP - 1354

EP - 1358

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this